Friday, May 1, 2026

THE SPY IN THE INNER CIRCLE : Has A South Korean Asset Infiltrated Pyongyang’s Second Tier?!

Ri Son-gwon has been appointed chairman of North Korea's KSDP, indicating a shift in his political influence and focus.

North Korea Burns Anti-Regime Leaflets: A Bold Statement or a Dangerous Escalation?

News1On July 15, the South Korean Ministry of Unification noted it as unusual that Kim Yo Jong, Depu ...

LG Uplus Wins Red Dot Design Award for U+tv User Experience

LG Uplus's U+tv wins the main prize at the 2025 Red Dot Design Awards for its exceptional UX and innovative design in IPTV services.

Tag: Therapeutics

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Verismo unveils preclinical data on improved antitumor efficacy and safety of blood cancer CAR-T at AACR

HLB Innovation's SynKIR-310 shows improved antitumor activity and safety in preclinical trials, achieving 100% survival in mice.

Nesuparib: The Game-Changing Cancer Treatment for Small Cell Lung Cancer Revealed at AACR 2026

Onconic Therapeutics reveals Nesuparib's promising preclinical results for small cell lung cancer, outperforming existing treatments significantly.

CG MedTech Acquires Human Tissue Processing Bank: What This Means for the Bio Sector in 2026

CG MedTech acquires a human tissue processing bank, expanding into bio business with ECM-based therapeutics and dental materials.

SK Biopharm Launches New Innovative Epilepsy Treatment Drug, Cenobamate, in China

SK Biopharm's epilepsy drug Cenobamate launches in China, marking a key milestone in its global expansion and commercialization strategy.

Emocog’s Cogthera is Revolutionizing MCI Treatment in 2026

Emocog develops innovative digital therapeutics for mild cognitive impairment, enhancing dementia care through early intervention and AI technology.

Revolutionary CAR-T Treatment SynKIR-310 Outperforms CD19 CAR-T: What This Means for Blood Cancer Patients

Verismo Therapeutics' SynKIR-310 shows superior anti-tumor effects in preclinical studies, promising a safer CAR-T therapy for blood cancers.

Verismo Therapeutics Welcomes FDA Approval Expert Dennis Williams: What This Means for CAR-T Cell Therapy

HLB Innovation appoints Dr. Dennis Williams as VP of Regulatory Affairs at Verismo Therapeutics to enhance global regulatory strategies.

How JNPMEDI Plans to Achieve 250% Revenue Growth in 2026: A Guide for Pharma Innovators

JNPMEDI aims to enhance its global role in drug and medical device development, achieving significant growth and expanding partnerships.

ST Pharm’s Record Growth: How RNA-Based Therapies Are Transforming the CDMO Market in 2026

ST Pharm reports record growth in oligonucleotide CDMO, driven by rising demand for RNA-based treatments for chronic diseases.

HLB’s Liragratinib: A Game-Changer in Cholangiocarcinoma Treatment Revealed at ASCO GI 2026!

HLB's lirafugratinib shows promise as a precision oncology drug, targeting FGFR2 in cancer treatment. FDA application expected soon.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.